Clinically used proton pump inhibitors (PPIs) are not perfectly suitable for prolonged acid
suppression because of the short plasma half-lives of 1–1.5
h. However, tenatoprazole, an imidazopyridine-type PPI, having a prolonged
plasma half-life, is a promising replacement of the currently used
PPIs. We have designed inhibitors that can possess imidazopyridine
and imidazophosphorine units and can ease the formation of disulfide
complex, which is one of the crucial steps toward the efficacy of
PPIs. The M11L-SMDWater/6-31++G(d,p)//M062X/6-31++G(d,p)
level of theory-calculated results demonstrated that the acid activation
of the imidazopyridine PPIs is complex than that of benzimidazole-type
PPIs because of the presence of additional nitrogen, which could be
protonated. However, the proton transfer from protonated pyridine
nitrogen (PyNH+) to benzimidazole nitrogen(3) (BzN(3))
is more energetically favorable than that of protonated benzimidazole
nitrogen(4) (BzN(4)H+) to BzN3 and the BzN(3)H+ further converts to the acid-activated sulfenic acid. It is to mention
here that the PyNH+ PPIs are more stable compared to BzN(4)H+ PPIs. Subsequently, the acid-activated sulfenic acid forms
the disulfide complex with the cysteine amino acid residue to inhibit
the gastric proton pump H+,K+-ATPase. The disulfide
complex formation (TS4) is the rate-determining step of the gastric
proton pump inhibition process. The density functional theory (DFT)
calculations also reveal that the acid activation and disulfide complex
formation of all of the PPIs are very similar to those of potent PPI
omeprazole. The free-energy activation barrier for tenatoprazole is
47.0 kcal/mol with respect to the preceding intermediate sulfenic
acid, and the disulfide complex is stable by 28.0 kcal/mol. The M11L-SMDWater/6-31++G(d,p) level of theory results reveal that the
disulfide complex formation of the imidazophosphorine type of PPIs
is marginally more favorable than that of the analogous imidazopyridine
type of PPIs. The newly designed inhibitor-3 and inhibitor-5 possess
the lowest activation free-energy barriers, i.e., 35.8 and 35.9 kcal/mol,
respectively, in the rate-determining steps (TS4) and also achieve
significant thermodynamic stability of the disulfide complex. Steered
molecular dynamics simulations performed with representative tenatoprazole
and inhibitor-5 corroborated the DFT results.